Vanessa Salinas-Luna
Pediatric Hematology-Oncology · Orange, CANPI 1952597858
Payments from drug & device makers
Across 636 payments — averaging $846.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$257K
- Bayer$104K
- Global Blood Therapeutics, Inc.$58K
- Novo Nordisk AS$47K
- Genentech USA, Inc.$26K
- Shire North American Group Inc$14K
- plus $34K from 22 others
What the payments were for
- Consulting fees$77,55123%
- Speaking & faculty fees$202,35459%
- Travel & lodging$52,44815%
- Food & beverage$11,0313%
- Education$2730%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 189 | $256,828 |
| Bayer | 87 | $103,534 |
| Global Blood Therapeutics, Inc. | 12 | $57,624 |
| Novo Nordisk AS | 181 | $46,578 |
| Genentech USA, Inc. | 40 | $26,024 |
| Shire North American Group Inc | 12 | $14,076 |
| Biomarin Pharmaceutical Inc. | 14 | $7,494 |
| Pfizer | 13 | $5,408 |
| Octapharma USA, Inc. | 13 | $4,552 |
| CSL Behring | 9 | $3,860 |
| Genentech, Inc. | 8 | $3,353 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $3,195 |
| Sanofi US Services Inc. | 1 | $1,992 |
| Bristol Myers Squibb | 1 | $1,902 |
| Novo Nordisk | 19 | $719 |
| Spark Therapeutics, Inc. | 5 | $284 |
| Agios Pharmaceuticals, Inc. | 6 | $262 |
| Novartis | 3 | $169 |
| Rigel Pharmaceuticals, Inc. | 2 | $140 |
| AstraZeneca | 1 | $122 |
| HEMA Biologics, LLC | 2 | $87 |
| Chiesi USA, Inc. | 3 | $51 |
| Bio Products Laboratory USA, Inc. | 2 | $47 |
| Vertex | 2 | $45 |
| Grifols USA, LLC | 2 | $43 |
| Sobi, Inc | 1 | $23 |
| Emmaus Medical, Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$538,445 in reported general payments places this provider in the 85th percentile of 307 pediatric hematology-oncology providers in California.
See all pediatric hematology-oncology providers in California →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PromactaEltrombopag Olamine | 12 | $75,481 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisPromacta | $169 | $75,48112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 307 pediatric hematology-oncology providers in California.
Other pediatric hematology-oncology in Orange
- Elyssa RubinOrange$1.1M
- van HuynhOrange$996K
- Mariko SatoOrange$694K
- Diane NugentOrange$652K
- Beth WingerSan Francisco$8.6M
- James GellerSan Diego$7.8M
- Norman LacayoPalo Alto$5M
- Alan WayneLos Angeles$3.8M
- Ami ShahPalo Alto$3.2M
- Philip PizzoPalo Alto$2.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.